Prophylactic treatment in Sweden - Overtreatment or optimal model?
Lee, C A ; Kessler, C M ; Varon, D ; Martinowitz, U ; Heim, M and Ljung, R.C.R. LU
(1998)
In Haemophilia
4(4).
p.409-412
- Abstract
- At the haemophilia centre in Malmo, Sweden, regular prophylactic treatment is begun at 1-1 1/4 years of age, before the onset of joint bleeds. The dose and dose interval are optimised by means of pharmacokinetic studies to determine the individual patient's FVIII or IX metabolism, the goal of maintaining a level > 1% of normal being taken as a guideline which experience has shown to yield satisfactory control of bleeding diathesis. An optimal model for prophylactic treatment needs to be applicable to haemophiliacs and acceptable to health authorities in a majority of the countries in the world. To fulfill these criteria, the Swedish model, which has been shown to yield most satisfactory outcome, can hopefully be further refined in the... (More)
- At the haemophilia centre in Malmo, Sweden, regular prophylactic treatment is begun at 1-1 1/4 years of age, before the onset of joint bleeds. The dose and dose interval are optimised by means of pharmacokinetic studies to determine the individual patient's FVIII or IX metabolism, the goal of maintaining a level > 1% of normal being taken as a guideline which experience has shown to yield satisfactory control of bleeding diathesis. An optimal model for prophylactic treatment needs to be applicable to haemophiliacs and acceptable to health authorities in a majority of the countries in the world. To fulfill these criteria, the Swedish model, which has been shown to yield most satisfactory outcome, can hopefully be further refined in the future. Were continuous infusion, using a recombinate concentrate with a prolonged half-life, technically feasible and socially acceptable to the child, we would probably have attained the optimal model of prophylactic treatment. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/a4f0e61d-3b3e-4a15-9295-7a1eef995a94
- author
- Lee, C A
; Kessler, C M
; Varon, D
; Martinowitz, U
; Heim, M
and Ljung, R.C.R.
LU
- organization
- publishing date
- 1998-11-25
- type
- Contribution to journal
- publication status
- published
- keywords
- Factor IX, Factor VIII, Haemophilia A, Haemophilia B, Prophylaxis, blood clotting factor, blood clotting factor 8, blood clotting factor 9, conference paper, continuous infusion, drug half life, hemarthrosis, hemophilia, human, metabolism, practice guideline, priority journal, prophylaxis, Sweden
- in
- Haemophilia
- volume
- 4
- issue
- 4
- pages
- 409 - 412
- publisher
- Wiley-Blackwell
- external identifiers
-
- scopus:0031856486
- ISSN
- 1351-8216
- DOI
- 10.1046/j.1365-2516.1998.440409.x
- language
- English
- LU publication?
- yes
- id
- a4f0e61d-3b3e-4a15-9295-7a1eef995a94
- date added to LUP
- 2016-11-25 14:54:13
- date last changed
- 2022-06-19 17:41:40
@article{a4f0e61d-3b3e-4a15-9295-7a1eef995a94,
abstract = {{At the haemophilia centre in Malmo, Sweden, regular prophylactic treatment is begun at 1-1 1/4 years of age, before the onset of joint bleeds. The dose and dose interval are optimised by means of pharmacokinetic studies to determine the individual patient's FVIII or IX metabolism, the goal of maintaining a level > 1% of normal being taken as a guideline which experience has shown to yield satisfactory control of bleeding diathesis. An optimal model for prophylactic treatment needs to be applicable to haemophiliacs and acceptable to health authorities in a majority of the countries in the world. To fulfill these criteria, the Swedish model, which has been shown to yield most satisfactory outcome, can hopefully be further refined in the future. Were continuous infusion, using a recombinate concentrate with a prolonged half-life, technically feasible and socially acceptable to the child, we would probably have attained the optimal model of prophylactic treatment.}},
author = {{Lee, C A and Kessler, C M and Varon, D and Martinowitz, U and Heim, M and Ljung, R.C.R.}},
issn = {{1351-8216}},
keywords = {{Factor IX; Factor VIII; Haemophilia A; Haemophilia B; Prophylaxis; blood clotting factor; blood clotting factor 8; blood clotting factor 9; conference paper; continuous infusion; drug half life; hemarthrosis; hemophilia; human; metabolism; practice guideline; priority journal; prophylaxis; Sweden}},
language = {{eng}},
month = {{11}},
number = {{4}},
pages = {{409--412}},
publisher = {{Wiley-Blackwell}},
series = {{Haemophilia}},
title = {{Prophylactic treatment in Sweden - Overtreatment or optimal model?}},
url = {{http://dx.doi.org/10.1046/j.1365-2516.1998.440409.x}},
doi = {{10.1046/j.1365-2516.1998.440409.x}},
volume = {{4}},
year = {{1998}},
}